{"id":989326,"date":"2026-08-02T19:19:16","date_gmt":"2026-08-02T19:19:16","guid":{"rendered":"https:\/\/one2one.health\/?p=989326"},"modified":"2026-08-08T22:57:35","modified_gmt":"2026-08-08T22:57:35","slug":"the-national-center-has-helped-thousands-tackle-obesity-in-qatar-2","status":"publish","type":"post","link":"https:\/\/one2one.health\/en\/2026\/08\/02\/the-national-center-has-helped-thousands-tackle-obesity-in-qatar-2\/","title":{"rendered":"WHO moves to back weight-loss drugs"},"content":{"rendered":"\t\t
\n\t\t\t\t
\n\t\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t
\n\t\t\t\t\t\t\t\t\t

Source: Al Jazeera Net <\/strong><\/p>

A draft guideline from the World Health Organization has emerged, indicating it will recommend the use of weight-loss medications for treating obesity in adults and urge countries to take the issue of obesity seriously as a chronic disease. <\/p>

A WHO expert committee concluded that popular GLP-1 drugs, which are medications based on mimicking glucagon-like peptide-1 hormone and were first developed by Novo Nordisk and Eli Lilly, are part of the solution for treating obesity in patients with a Body Mass Index (BMI) of 30 or higher, alongside lifestyle and behavioral counseling. <\/p>

Reuters first reported in May that the WHO was likely to take this step.<\/p>

In the draft guidelines, published online and open for consultation until September 27, the WHO stated that addressing obesity is often shaped by outdated views that portray it as a lifestyle problem. <\/p>

Instead, the organization said that obesity is a “chronic, progressive, and relapsing disease” affecting over a billion people worldwide in both high- and low-income countries and contributing to millions of preventable deaths.<\/p>

The organization recommended the use of these drugs for treating obesity for the first time, describing it as a significant step towards developing a global standard of care. The organization is currently developing separate guidelines for treating children and adolescents. <\/p>

The WHO guidelines apply only to those with a BMI above 30, but in some high-income countries, such as the United States, these drugs are also recommended for those with a BMI between 27 and 30 who suffer from at least one weight-related medical condition. <\/p>

Earlier this month, the WHO did not go so far as to add these drugs for obesity treatment to its essential medicines list, a separate list that includes medicines that should be available in all functioning healthcare systems. <\/p>

However, it has already added them for patients with type 2 diabetes, the disease for which companies originally developed these drugs, if combined with another health condition. <\/p>

The organization added that this indicates which patients will benefit most from these expensive treatments, noting that high prices limit access to medicines in low- and middle-income countries. <\/p>

<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"

Source: Al Jazeera Net A draft guideline from the World Health Organization has emerged, indicating it will recommend the use of weight-loss medications for treating obesity in adults and urge countries to take the issue of obesity seriously as a chronic disease. A WHO expert committee concluded that popular GLP-1 drugs, which are medications based…<\/p>\n","protected":false},"author":2,"featured_media":989323,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-989326","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-1"],"_links":{"self":[{"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/posts\/989326","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/comments?post=989326"}],"version-history":[{"count":3,"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/posts\/989326\/revisions"}],"predecessor-version":[{"id":989447,"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/posts\/989326\/revisions\/989447"}],"wp:attachment":[{"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/media?parent=989326"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/categories?post=989326"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/one2one.health\/en\/wp-json\/wp\/v2\/tags?post=989326"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}